



## BUMITAMA AGRI LTD.

### Unaudited Financial Statements for the Second Half of the year (“2H”) and Full Year (“FY”) Ended 31 December 2020

#### 1(a)(i) Income statement (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group					
	2nd Half			FY		
	2020 IDR million	2019 IDR million	Change (%)	2020 IDR million	2019 IDR million	Change (%)
<b>Revenue</b>	5,099,260	4,235,603	20.4%	9,101,746	7,691,341	18.3%
Cost of sales	(3,611,491)	(3,146,036)	14.8%	(6,575,599)	(5,958,249)	10.4%
<b>Gross profit</b>	<b>1,487,769</b>	<b>1,089,567</b>	<b>36.5%</b>	<b>2,526,147</b>	<b>1,733,092</b>	<b>45.8%</b>
Interest income	102,510	99,908	2.6%	202,205	186,669	8.3%
Fair value changes in biological assets	25,690	19,906	29.1%	25,690	19,906	29.1%
Selling expenses	(154,812)	(178,663)	-13.3%	(295,770)	(352,861)	-16.2%
General and administrative expenses	(171,400)	(132,687)	29.2%	(312,461)	(294,554)	6.1%
Finance cost	(80,999)	(125,593)	-35.5%	(178,955)	(240,140)	-25.5%
Foreign exchange gain/(loss)	53,904	64,464	-16.4%	(49,028)	159,714	n.m.
Other income/(expenses), net	6,211	(21,580)	n.m.	12,712	(18,660)	n.m.
<b>Profit before income tax</b>	<b>1,268,873</b>	<b>815,322</b>	<b>55.6%</b>	<b>1,930,540</b>	<b>1,193,166</b>	<b>61.8%</b>
Income tax expense	(429,001)	(260,271)	64.8%	(568,135)	(352,825)	61.0%
<b>Profit for the period/year</b>	<b>839,872</b>	<b>555,051</b>	<b>51.3%</b>	<b>1,362,405</b>	<b>840,341</b>	<b>62.1%</b>
<b>Attributable to:</b>						
Owners of the Company	685,142	451,068	51.9%	1,126,393	686,313	64.1%
Non-controlling interests	154,730	103,983	48.8%	236,012	154,028	53.2%
	<b>839,872</b>	<b>555,051</b>	<b>51.3%</b>	<b>1,362,405</b>	<b>840,341</b>	<b>62.1%</b>

n.m. – not meaningful

#### Additional Information

	Group					
	2nd Half			FY		
	2020 IDR million	2019 IDR million	Change (%)	2020 IDR million	2019 IDR million	Change (%)
Profit before income tax	1,268,873	815,322	55.6%	1,930,540	1,193,166	61.8%
Depreciation and amortisation	329,693	301,789	9.2%	644,862	597,297	8.0%
Foreign exchange (gain)/loss	(53,904)	(64,464)	-16.4%	49,028	(159,714)	n.m.
Finance cost	80,999	125,593	-35.5%	178,955	240,140	-25.5%
Interest income	(102,510)	(99,908)	2.6%	(202,205)	(186,669)	8.3%
Fair value changes in biological assets	(25,690)	(19,906)	29.1%	(25,690)	(19,906)	29.1%
Other expense	-	29,589	-100.0%	-	29,589	-100.0%
<b>EBITDA</b>	<b>1,497,461</b>	<b>1,088,015</b>	<b>37.6%</b>	<b>2,575,490</b>	<b>1,693,903</b>	<b>52.0%</b>

n.m. – not meaningful

**1(a)(ii) A statement of total comprehensive income together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Statement of comprehensive income:	Group					
	2nd Half			FY		
	2020 IDR million	2019 IDR million	Change (%)	2020 IDR million	2019 IDR million	Change (%)
<b>Profit for the period/year</b>	<b>839,872</b>	<b>555,051</b>	<b>51.3%</b>	<b>1,362,405</b>	<b>840,341</b>	<b>62.1%</b>
<b>Other comprehensive income</b>						
<b>Item that may be reclassified subsequently to profit or loss:</b>						
Foreign currency translation gain	42,402	31,075	36.5%	10,666	71,266	-85.0%
Fair value reserve on derivative financial assets/liabilities	40,712	10,030	n.m.	(2,223)	8,174	n.m.
<b>Item that will not be reclassified to profit or loss:</b>						
Re-measurement loss on defined benefit plans	(10,722)	(6,586)	62.8%	(10,722)	(6,586)	62.8%
<b>Other comprehensive income for the period/year, net of tax</b>	<b>72,392</b>	<b>34,519</b>	<b>n.m.</b>	<b>(2,279)</b>	<b>72,854</b>	<b>n.m.</b>
<b>Total comprehensive income for the period/year</b>	<b>912,264</b>	<b>589,570</b>	<b>54.7%</b>	<b>1,360,126</b>	<b>913,195</b>	<b>48.9%</b>
<b>Attributable to:</b>						
Owners of the Company	758,306	486,529	55.9%	1,124,886	760,109	48.0%
Non-controlling interests	153,958	103,041	49.4%	235,240	153,086	53.7%
	<b>912,264</b>	<b>589,570</b>	<b>54.7%</b>	<b>1,360,126</b>	<b>913,195</b>	<b>48.9%</b>

*n.m. – not meaningful*

**1(b)(i) Statement of Financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

	Group		Company	
	31-Dec-2020	31-Dec-2019	31-Dec-2020	31-Dec-2019
	IDR million	IDR million	IDR million	IDR million
<b>ASSETS</b>				
<b>Non-current assets</b>				
Plasma receivables	2,639,567	2,441,886	-	-
Property, plant and equipment	3,813,214	3,525,804	2,250	3,155
Bearer plants	7,725,442	7,537,293	-	-
Land use rights	971,853	954,098	-	-
Investment in subsidiaries	-	-	2,075,776	2,045,754
Intangible assets	182,606	177,948	-	-
Derivative financial assets	72,763	30,442	72,763	30,442
Deferred tax assets	209,491	270,739	-	-
Due from subsidiaries	-	-	6,467,014	7,319,619
<b>Total Non-current assets</b>	<b>15,614,936</b>	<b>14,938,210</b>	<b>8,617,803</b>	<b>9,398,970</b>
<b>Current assets</b>				
Biological assets	294,010	268,320	-	-
Inventories	852,402	658,834	-	-
Deferred charges	7,831	7,312	-	-
Trade and other receivables	70,637	349,920	327	333
Due from related companies	50	50	-	-
Plasma receivables	64,496	118,974	-	-
Prepayments and advances	31,610	37,957	189	132
Dividend receivables	-	-	442,315	209,790
Prepaid taxes	504,875	560,838	58	53
Cash and short-term deposits	791,953	503,753	274,427	35,293
<b>Total Current assets</b>	<b>2,617,864</b>	<b>2,505,958</b>	<b>717,316</b>	<b>245,601</b>
<b>Total Assets</b>	<b>18,232,800</b>	<b>17,444,168</b>	<b>9,335,119</b>	<b>9,644,571</b>
<b>LIABILITIES AND EQUITY</b>				
<b>Current liabilities</b>				
Loans and borrowings	282,100	625,545	282,100	625,545
Trade and other payables	598,755	757,143	2,158	31
Accrued operating expenses	221,201	192,590	50,259	51,604
Dividend payables to non-controlling interests	54,595	22,015	-	-
Sales advances	281,120	57,289	-	-
Income taxes payable	284,301	65,939	37	170
<b>Total Current liabilities</b>	<b>1,722,072</b>	<b>1,720,521</b>	<b>334,554</b>	<b>677,350</b>
<b>Non-current liabilities</b>				
Deferred tax liabilities	137,607	125,011	-	-
Loans and borrowings	3,282,436	3,720,255	3,282,436	3,720,255
Islamic medium term notes	2,443,238	2,376,514	2,443,238	2,376,514
Post employment benefits	101,092	70,687	-	-
Derivative financial liabilities	12,512	-	12,512	-
<b>Total Non-current liabilities</b>	<b>5,976,885</b>	<b>6,292,467</b>	<b>5,738,186</b>	<b>6,096,769</b>
<b>Total Liabilities</b>	<b>7,698,957</b>	<b>8,012,988</b>	<b>6,072,740</b>	<b>6,774,119</b>
<b>Net Assets</b>	<b>10,533,843</b>	<b>9,431,180</b>	<b>3,262,379</b>	<b>2,870,452</b>
<b>Equity attributable to owners of the Company</b>				
Share capital	1,807,045	1,807,045	1,807,045	1,807,045
Treasury shares	(161,366)	(147,449)	(161,366)	(147,449)
Other reserves	(213,435)	(201,717)	2,641	4,864
Retained earnings	7,764,128	6,814,530	561,915	223,151
Foreign currency translation reserve	(179,697)	(190,363)	1,052,144	982,841
	<b>9,016,675</b>	<b>8,082,046</b>	<b>3,262,379</b>	<b>2,870,452</b>
<b>Non-controlling interests</b>	<b>1,517,168</b>	<b>1,349,134</b>	<b>-</b>	<b>-</b>
<b>Total Equity</b>	<b>10,533,843</b>	<b>9,431,180</b>	<b>3,262,379</b>	<b>2,870,452</b>

**1(b)(ii) Aggregate amount of group's borrowings and debt securities.**

- Amount repayable in one year or less, or on demand
- Amount repayable after one year

	31-Dec-2020 IDR Million	31-Dec-2019 IDR Million
Amount due within one year		
Unsecured	282,100	625,545
<b>Total</b>	<b>282,100</b>	<b>625,545</b>
Amount due more than one year		
Unsecured	5,725,674	6,096,769
<b>Total</b>	<b>5,725,674</b>	<b>6,096,769</b>

The unsecured borrowings contain negative pledge clauses.

**1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year**

CASH FLOWS	Group			
	2nd Half		FY	
	2020	2019	2020	2019
	IDR million	IDR million	IDR million	IDR million
<b>Cash flows from operating activities</b>				
Cash receipts from customers	5,191,843	4,151,495	9,605,640	7,872,291
Cash payments to suppliers, employees and for other operating expenses	(3,704,646)	(3,177,855)	(6,996,857)	(6,278,395)
Income tax paid	(51,918)	(180,265)	(162,986)	(387,985)
<b>Net cash flows generated from operating activities</b>	<b>1,435,279</b>	<b>793,375</b>	<b>2,445,797</b>	<b>1,205,911</b>
<b>Cash flows from investing activities</b>				
Decrease/(increase) in plasma receivables	137,263	(211,357)	(110,735)	(463,224)
Investment in intangible assets	(7,732)	(3,522)	(8,031)	(3,522)
Investment in bearer plants	(223,594)	(166,936)	(381,092)	(319,749)
Investment in property, plant and equipment	(327,389)	(214,411)	(598,000)	(346,561)
Investment in land use rights	(15,538)	(15,237)	(35,050)	(34,186)
Proceeds from sale of shares and loan repayment from associate company	-	55,576	-	55,576
Interest received	102,510	97,760	202,205	181,520
<b>Net cash flows used in investing activities</b>	<b>(334,480)</b>	<b>(458,127)</b>	<b>(930,703)</b>	<b>(930,146)</b>
<b>Cash flows from financing activities</b>				
Proceeds from loans and borrowings	146,550	826,948	785,475	4,180,938
Repayment of loans and borrowings	(867,610)	(917,945)	(1,648,790)	(1,414,980)
Proceeds from issuance of Islamic Medium Term Notes	-	2,362,606	-	2,362,606
Repayment of Islamic Medium Term Notes	-	(2,261,097)	-	(4,454,303)
Payment of dividend	(118,802)	(73,710)	(254,730)	(442,107)
Contribution from non-controlling interests	34,421	-	54,526	-
Buy-back of ordinary shares	-	-	(13,917)	(13,736)
Interest paid	(74,595)	(130,740)	(170,528)	(286,920)
<b>Net cash flows used in financing activities</b>	<b>(880,036)</b>	<b>(193,938)</b>	<b>(1,247,964)</b>	<b>(68,502)</b>
<b>Net increase in cash and cash equivalents</b>	<b>220,763</b>	<b>141,310</b>	<b>267,130</b>	<b>207,263</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>3,773</b>	<b>(1,013)</b>	<b>21,070</b>	<b>(2,563)</b>
<b>Cash and cash equivalents at beginning of period/year</b>	<b>567,417</b>	<b>363,456</b>	<b>503,753</b>	<b>299,053</b>
<b>Cash and cash equivalents at end of period/year</b>	<b>791,953</b>	<b>503,753</b>	<b>791,953</b>	<b>503,753</b>

**1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)**

Cash Flows from Operating Activities:	Group			
	2nd Half		FY	
	2020	2019	2020	2019
	IDR million	IDR million	IDR million	IDR million
Profit before income tax	1,268,873	815,322	1,930,540	1,193,166
Depreciation and amortisation	329,693	301,789	644,862	597,297
Finance cost	80,999	125,593	178,955	240,140
Interest income	(102,510)	(99,908)	(202,205)	(186,669)
Post employment benefits	22,842	19,575	22,842	19,575
Unrealized foreign exchange (gain)/loss	(52,056)	209	82,271	(125,553)
Other expense	-	29,589	-	29,589
Fair value changes in biological assets	(25,690)	(19,906)	(25,690)	(19,906)
Operating cash flows before working capital changes	<b>1,522,151</b>	<b>1,172,263</b>	<b>2,631,575</b>	<b>1,747,639</b>
Decrease/(increase) in:				
- Trade and other receivables	19,637	(95,243)	279,721	128,597
- Inventories	7,830	70,363	(193,568)	(66,434)
- Prepaid taxes	116,684	191,140	55,963	(17,361)
- Prepayments and advances	(17,618)	(10,276)	6,349	(19,340)
- Deferred charges	(62)	996	(519)	1,223
(Decrease)/increase in:				
- Trade and other payables	(18,661)	(126,508)	(159,146)	(15,047)
- Accrued operating expenses	(41,400)	(70,929)	(101,948)	(147,986)
- Other taxes payable	(170,795)	(161,007)	(127,171)	(55,381)
- Sales advances	75,736	9,216	223,832	44,361
Employee benefits contribution paid	(6,305)	(6,375)	(6,305)	(6,375)
Cash flows generated from operations	<b>1,487,197</b>	<b>973,640</b>	<b>2,608,783</b>	<b>1,593,896</b>
Income tax paid	(51,918)	(180,265)	(162,986)	(387,985)
<b>Net cash flows generated from operating activities</b>	<b>1,435,279</b>	<b>793,375</b>	<b>2,445,797</b>	<b>1,205,911</b>

**1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Group	----- Attributable to owners of the Group -----						Non-controlling interests	Total equity
	Share capital	Treasury shares	Retained earnings	Other reserves	Foreign currency translation reserve	Total share capital and reserves		
	IDR million	IDR million	IDR million	IDR million	IDR million	IDR million		
<b>Opening balance at 1 January 2020</b>	<b>1,807,045</b>	<b>(147,449)</b>	<b>6,814,530</b>	<b>(201,717)</b>	<b>(190,363)</b>	<b>8,082,046</b>	<b>1,349,134</b>	<b>9,431,180</b>
Profit for the year	-	-	1,126,393	-	-	1,126,393	236,012	1,362,405
<b>Other comprehensive income:</b>								
Foreign currency translation gain	-	-	-	-	10,666	10,666	-	10,666
Fair value reserve on derivative financial assets/liabilities	-	-	-	(2,223)	-	(2,223)	-	(2,223)
Re-measurement loss on defined benefit plan	-	-	(9,950)	-	-	(9,950)	(772)	(10,722)
Total comprehensive income for the year, net of tax	-	-	1,116,443	(2,223)	10,666	1,124,886	235,240	1,360,126
<b>Contributions by and distributions to owners:</b>								
Contribution from non-controlling interests	-	-	-	-	-	-	54,526	54,526
Buy-back of ordinary shares	-	(13,917)	-	-	-	(13,917)	-	(13,917)
Dividends on ordinary shares	-	-	(166,845)	-	-	(166,845)	(131,227)	(298,072)
<b>Changes in ownership interest in subsidiaries:</b>								
Decrease in ownership in subsidiary without a change in control	-	-	-	(9,495)	-	(9,495)	9,495	-
<b>Closing balance at 31 December 2020</b>	<b>1,807,045</b>	<b>(161,366)</b>	<b>7,764,128</b>	<b>(213,435)</b>	<b>(179,697)</b>	<b>9,016,675</b>	<b>1,517,168</b>	<b>10,533,843</b>
<b>Opening balance at 1 January 2019</b>	<b>1,807,045</b>	<b>(133,713)</b>	<b>6,569,298</b>	<b>(209,891)</b>	<b>(261,629)</b>	<b>7,771,110</b>	<b>1,228,618</b>	<b>8,999,728</b>
Profit for the year	-	-	686,313	-	-	686,313	154,028	840,341
<b>Other comprehensive income:</b>								
Foreign currency translation gain	-	-	-	-	71,266	71,266	-	71,266
Fair value reserve on derivative financial assets	-	-	-	8,174	-	8,174	-	8,174
Re-measurement gain on defined benefit plan	-	-	(5,644)	-	-	(5,644)	(942)	(6,586)
Total comprehensive income for the year, net of tax	-	-	680,669	8,174	71,266	760,109	153,086	913,195
<b>Distribution to owners:</b>								
Buy-back of ordinary shares	-	(13,736)	-	-	-	(13,736)	-	(13,736)
Dividends on ordinary shares	-	-	(435,437)	-	-	(435,437)	(32,570)	(468,007)
<b>Closing balance at 31 December 2019</b>	<b>1,807,045</b>	<b>(147,449)</b>	<b>6,814,530</b>	<b>(201,717)</b>	<b>(190,363)</b>	<b>8,082,046</b>	<b>1,349,134</b>	<b>9,431,180</b>

Company	----- Attributable to owners of the Company -----					
	Share capital	Treasury shares	Retained earnings	Other reserves	Foreign currency translation reserves	Total share capital and reserves
	IDR million	IDR million	IDR million	IDR million	IDR million	IDR million
<b>Opening balance at 1 January 2020</b>	<b>1,807,045</b>	<b>(147,449)</b>	<b>223,151</b>	<b>4,864</b>	<b>982,841</b>	<b>2,870,452</b>
Profit for the year	-	-	505,609	-	-	505,609
<b>Other comprehensive income:</b>						
Foreign currency translation gain	-	-	-	-	69,303	69,303
Fair value reserve on derivative financial assets/liabilities	-	-	-	(2,223)	-	(2,223)
Total comprehensive income for the year, net of tax	-	-	505,609	(2,223)	69,303	572,689
<b>Distribution to owners:</b>						
Buy-back of ordinary shares	-	(13,917)	-	-	-	(13,917)
Dividends on ordinary shares	-	-	(166,845)	-	-	(166,845)
<b>Closing balance at 31 December 2020</b>	<b>1,807,045</b>	<b>(161,366)</b>	<b>561,915</b>	<b>2,641</b>	<b>1,052,144</b>	<b>3,262,379</b>
<b>Opening balance at 1 January 2019</b>	<b>1,807,045</b>	<b>(133,713)</b>	<b>481,822</b>	<b>(3,310)</b>	<b>1,117,315</b>	<b>3,269,159</b>
Profit for the year	-	-	176,766	-	-	176,766
<b>Other comprehensive income:</b>						
Foreign currency translation loss	-	-	-	-	(134,474)	(134,474)
Fair value reserve on derivative financial assets	-	-	-	8,174	-	8,174
Total comprehensive income for the year, net of tax	-	-	176,766	8,174	(134,474)	50,466
<b>Distribution to owners:</b>						
Buy-back of ordinary shares	-	(13,736)	-	-	-	(13,736)
Dividends on ordinary shares	-	-	(435,437)	-	-	(435,437)
<b>Closing balance at 31 December 2019</b>	<b>1,807,045</b>	<b>(147,449)</b>	<b>223,151</b>	<b>4,864</b>	<b>982,841</b>	<b>2,870,452</b>

**1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

There was no change in in the Company's share capital since the end of the last report period as at 30 June 2020. Details of the treasury shares as at 31 December 2020 and 2019 were as follows:

	Company	
	Number of shares	
	31-Dec-2020	31-Dec-2019
Treasury shares	23,387,800	20,034,800
Issued ordinary shares excluding treasury shares	1,734,144,044	1,737,497,044
<b>Issued ordinary shares</b>	<b>1,757,531,844</b>	<b>1,757,531,844</b>

The Company did not have any outstanding convertibles against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediate preceding financial year.

**1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

	Company	
	Number of shares	
	31-Dec-2020	31-Dec-2019
Issued ordinary shares excluding treasury shares	1,734,144,044	1,737,497,044

**1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

There were no treasury shares which were sold, transferred, cancelled or used in the current financial period.

**1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.**

Not applicable.

**2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The financial statements presented above have not been audited or reviewed by the Company's auditors.



3. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).

Not applicable.

- 3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:—

- (a) Updates on the efforts taken to resolve each outstanding audit issue.  
 (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

The Group has applied the same accounting policies and methods of computation in the preparation of the financial statements as at 31 December 2019, except for the new and revised Singapore Financial Reporting Standards (International) ("SFRS(I)") that are effective for annual periods beginning on or after 1 January 2020. The adoption of these standards has no significant impact to the Group's consolidated financial statements.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Not applicable.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends; (a) based on weighted average number of shares and (b) on fully diluted basis (detailing any adjustments made to the earnings)

Earning per share for the period (weighted average number of shares)	2nd Half		FY	
	2020	2019	2020	2019
Based on weighted average number of share (in IDR)	392	258	645	392
Weighted number of shares	1,747,375,863	1,749,468,694	1,746,621,047	1,749,227,435

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:

- (a) Current financial period reported on; and  
 (b) Immediately preceding financial year.

Net asset value per share	Group		Company	
	31-Dec-2020	31-Dec-2019	31-Dec-2020	31-Dec-2019
Net asset value per ordinary share (in IDR)	5,199	4,652	1,881	1,652
Number of issued ordinary shares *	1,734,144,044	1,737,497,044	1,734,144,044	1,737,497,044

\* excluding Treasury Shares

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:
- (a) Any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
  - (b) Any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

## REVIEW OF INCOME STATEMENT

### Overview

The Group's overall performance during the second half of the year ("2H2020") and full year of 2020 ("FY2020") had significantly improved compared to previous corresponding period, mainly contributed by the strengthening of palm oil prices.

### Revenue

Revenue increased by 20.4% to IDR 5,099 billion in 2H2020 and by 18.3% to IDR 9,102 billion in FY2020 compared to previous corresponding period/year, mainly attributable to the increase in average selling prices of Crude Palm Oil ("CPO") and Palm Kernel ("PK"). The breakdown of revenue for 2H2020 and FY2020 compared to the previous corresponding period, was as follow:

Revenue	2H2020	2H2019	Change	FY2020	FY2019	Change
	IDR million	IDR million	(%)	IDR million	IDR million	(%)
CPO	4,584,155	3,865,746	18.6%	8,188,808	6,944,502	17.9%
PK	515,105	369,857	39.3%	912,938	746,839	22.2%
<b>Total</b>	<b>5,099,260</b>	<b>4,235,603</b>	<b>20.4%</b>	<b>9,101,746</b>	<b>7,691,341</b>	<b>18.3%</b>
<b>Sales Volume</b>						
	2H2020	2H2019	Change	FY2020	FY2019	Change
	mt	mt	(%)	mt	mt	(%)
CPO	549,738	568,394	-3.3%	982,578	1,037,050	-5.3%
PK	113,817	117,182	-2.9%	209,084	218,657	-4.4%
<b>Average sales prices</b>						
	2H2020	2H2019	Change	FY2020	FY2019	Change
	IDR / kg	IDR / kg	(%)	IDR / kg	IDR / kg	(%)
CPO	8,339	6,801	22.6%	8,334	6,696	24.5%
PK	4,526	3,156	43.4%	4,366	3,416	27.8%

**Cost of Sales**

Cost of sales comprised mainly costs for plantation maintenance, harvesting, plantation overhead, depreciation and amortisation, milling and Fresh Fruit Bunches (“FFB”) purchased externally (from plasma and external parties).

**Interest Income**

Interest income mainly consist of interest income earned from advances extended to the plasma farmers and fund placement in banks.

**Fair Value Changes in Biological Assets**

In accordance with SFRS(I) 1-41, the agriculture produce growing on bearer plants are measured at fair value less cost to sell.

The Group recorded an increase in fair value changes in biological assets amounted to IDR 26 billion based on market value of the agriculture produce as at 31 December 2020.

**Selling Expenses**

Selling expenses mainly comprised of freight and loading expenses. The decrease in selling expenses during the year was mainly due to lower sales volume.

**General and Administrative Expenses**

General and administrative expenses increased by 29.2% to IDR 171 billion in 2H2020 and by 6.1% to IDR 312 billion in FY2020 mainly due to increase in employee benefits as well as increase in tariff especially for Land and Building.

**Finance Cost**

Finance cost decreased by 35.5% to IDR 81 billion in 2H2020 and by 25.5% to IDR 179 billion in FY2020 mainly attributable to lower interest rate arising from lower London Interbank Offered Rate (“LIBOR”).

**Foreign Exchange Gain/(Loss)**

The appreciation of IDR against USD in 2H2020 resulted in the Group’s net foreign exchange gain of IDR 54 billion. On the other hand, IDR depreciated against USD in FY2020 which has brought the Group to recognise net foreign exchange loss of IDR 49 billion at the end of the year.

**Income Tax Expense**

The Group recorded an increase in income tax expense to IDR 429 billion in 2H2020 and IDR 568 billion in FY2020, as the result of increase in profit before income tax during the period.

## REVIEW OF STATEMENT OF FINANCIAL POSITION

### Non-Current Assets

As at 31 December 2020, the Group's total non-current assets increased by IDR 677 billion from IDR 14,938 billion to IDR 15,615 billion, mainly due to increase in plasma receivables, property, plant and equipment ("PPE") as well as bearer plants. The increase in plasma receivables, PPE and bearer plants was arising from advances given to plasma farmers for the maintenance of immature plasma plantation, construction and extension of some mills and development cost incurred for immature plantations, respectively.

### Current Assets

The increase in current assets by IDR 112 billion as at 31 December 2020 from IDR 2,506 billion to IDR 2,618 billion was mainly due to increase in cash and short-term deposits, inventories, biological assets which was offset by the decrease in trade and other receivables with improvement in sales collection compared to prior year. Refer to the cash flow section for movement in cash and short-term deposit.

Inventories mainly consist of palm products for delivery in the following month and fertilisers for application in 1<sup>st</sup> quarter of year 2021. The increase in biological assets was mainly due to the increase in CPO price during the year.

### Current Liabilities

As at 31 December 2020, the Group's total current liabilities increased to IDR 1,722 billion, mainly due to increase in sales advances arising from improved sales revenue and income taxes payable which was offset by the decrease in loans and borrowings due to bank loan repayment made during the period and improved payments to supplier during the year.

### Non-Current Liabilities

As at 31 December 2020, the Group's total non-current liabilities decreased by IDR 316 billion from IDR 6,292 billion to IDR 5,977 billion mainly due to reclassification of bank loans based on the maturity date of the loans.

## REVIEW OF STATEMENT OF CASH FLOW

The Group reported a net increase in cash and cash equivalents of IDR 267 billion as at 31 December 2020, bringing the cash and bank balances to IDR 792 billion, as follows:

- The Group recorded higher net cash flows generated from operating activities amounting to IDR 1,435 billion in 2H2020 and IDR 2,446 billion in FY2020 mainly due to the increase in cash collection from customers arising from higher revenue during the period and lower income tax paid due to Covid-19 pandemic incentives received from Indonesian Government.
- The Group recorded lower net cash flows used in investing activities amounting to IDR 334 billion in 2H2020 due to lower advances given to plasma farmers as a result of improvement in CPO price. In FY2020, the Group recorded slightly higher net cash flows used in investing activities amounting to IDR 931 billion which was mainly due to increased purchase of PPE related to construction and extension of some mills.
- The Group recorded net cash flows used in financing activities amounting to IDR 880 billion in 2H2020 and IDR 1,248 billion in FY2020 which mainly comprises of bank loan repayment as well as dividend and interest paid during the year.

**9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not applicable.

**10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The Covid-19 pandemic continued to create uncertainty and impact global economies and societies since March 2020. The tight supply of palm oil and other vegetable oils restocking had pushed CPO prices higher in 2020. We anticipate volatility of palm oil prices with some contraction of economics due to lockdown imposition in early 2021 and improvement in palm supply from second quarter of 2021. Nevertheless, palm oil prices will be supported by Indonesia B30 biodiesel mandate.

The Group believes the long-term fundamentals of the palm oil industry remain positive and the Company will continue to focus on business continuity, safety and health of its employees, drive for efficiency and innovation, processes improvement with latest technologies in its workplace and cost management.

**11. Dividend****(a) Current Financial Period Reported On**

Any dividend declared for the current financial period reported on?

Yes.

The Directors have recommended for the Company to pay a final dividend in respect of the financial year ended 31 December 2020.

The payment of the dividend will be subject to the approval by shareholders at the forthcoming AGM to be convened in April 2021.

**(b) Corresponding Period of the Immediately Preceding Financial Year**

Any dividend declared for the corresponding period of the immediately preceding financial year?

<b>FY2019</b>	
Name of Dividend	Final dividend
Dividend Type	Cash
Dividend amount per share	SGD 0.005
Payment Type	Tax Exempted (1-tier)

**(c) Date payable**

To be announced later.

**(d) Books closure date**

To be announced later.

**12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision**

Not applicable.

**13. Disclosure of the aggregate value of the transactions conducted under the shareholders' mandate for interested person transaction as required under Rule 920(1)(a)(ii) of the Listing Manual**

The Group has the following interested person transactions ("IPT") for FY2020:

Name of interested person	Nature of the relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920 of the Listing Manual)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 of the Listing Manual during the financial year under review (excluding transactions less than S\$100,000)
		in IDR million	in IDR million
Mr Gunardi Hariyanto Lim <sup>(1)</sup>	Family relationship with the controlling shareholder of the Company	2,400	Nil
Goldwood Investments Ltd <sup>(2)</sup>	Related company	2,050	Nil
IOI Corporation Berhad <sup>(3)</sup>	Controlling shareholder of the Company	Nil	Nil
PT Lima Srikandi Jaya <sup>(4)</sup>	Related company	7,200	Nil
<b>TOTAL</b>		<b>11,650</b>	<b>Nil</b>

Notes:

\*For illustrative purpose the aggregate value of all interested person transactions, conducted under the Shareholders' Mandate during the financial year under review using the current period average rate

- (1) In respect of the aggregate rent paid by the Group to Mr. Gunardi Hariyanto Lim for office space in Indonesia pursuant to the lease agreement between Mr. Gunardi Hariyanto Lim and PT Bumitama Gunajaya Agro.
- (2) In respect of the aggregate rent paid by the Group to Goldwood Investments Ltd for office space in Singapore pursuant to the lease agreement between Goldwood Investments Ltd and the Company.
- (3) In respect of transactions conducted pursuant to the Shareholders' Mandate for transactions with IOI Corporation Berhad and its Associates (as described in the Prospectus).
- (4) In respect of the rental agreement of barge transactions involving PT Lima Srikandi Jaya which is one of the subsidiaries of Harita Group. Harita Group is owned by Lim family and also one of the Company's controlling shareholders.

**14. Undertaking Confirmation Statement from all its directors and executive officers under Rule 720(1)**

The Company has procured undertakings from all its directors and executive officer (in the format set out in Appendix 7.7) under Rule 720(1) of the Listing Manual.

**ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT**

- 15. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year.**

The Group's primary business activities are cultivating and harvesting palm trees, processing FFB from our oil palm plantations, our plasma plantations, and third parties into CPO and PK, and selling CPO and PK in Indonesia. Accordingly, no segmental information is presented as it is not meaningful.

- 16. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.**

Not applicable.

- 17. A breakdown of sales**

	The Group		
	FY2020	FY2019	% Increase / (Decrease)
	IDR million	IDR million	IDR million
(a) Sales reported for the first half year	4,002,486	3,455,738	15.8%
(b) Operating profit before deducting minority interests reported for the first half year	522,533	285,290	83.2%
(c) Sales reported for the second half year	5,099,260	4,235,603	20.4%
(d) Operating profit before deducting minority interests reported for the second half year	839,872	555,051	51.3%

- 18. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:**

Please refer to Para. 11 above.



19. **Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make an appropriate negative statement.**

Name	Age	Family relationship with any director and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year.
<b>Lim Liana Sarwono</b>	68	The Sister of Lim Gunawan Hariyanto, Executive Chairman and CEO of BAL, Lim Christina Hariyanto, Executive Director of BAL and daughter of Dr. Lim Hariyanto Wijaya Sarwono, a controlling shareholder of BAL.	Senior Purchasing Manager since 1998.  - Responsible for securing quality purchases at reasonable prices.	No Change
<b>Gunardi Hariyanto Lim</b>	55	The Brother of Lim Gunawan Hariyanto, Executive Chairman and CEO of BAL, and Lim Christina Hariyanto, Executive Director of BAL, and son of Dr. Lim Hariyanto Wijaya Sarwono, a controlling shareholder of BAL	Chief Commissioner of PT Bumitama Gunajaya Agro since 2018  - Supervising commissioners and the company in accordance with the articles of association; - Collating advises from other commissioner and shares this advice to the board of directors; and although not part of the daily company management but do provide oversight on management policies.	No Change

**For and on behalf of the Board of Directors**

**Lim Gunawan Hariyanto**  
Executive Chairman and CEO  
22 February 2021

**Lee Lap Wah George**  
Lead Independent Director